Quarterly & Annual Financial Results
Morepen Laboratories Q4 Net Profit Surges 69% as CDMO Program Enters Commercial Execution Phase
NSE
morepenlab
BSE
500288
Morepen Laboratories reported strong Q4 FY26 performance with net profit rising 69% YoY to ₹20 crore and gross revenue increasing 22% YoY to ₹472 crore. The company highlighted commercial execution under its long-duration CDMO manufacturing partnership, strong growth in the Medical Devices business, capacity expansion initiatives and proposed a 10% dividend for FY26.
PRICE-SENSITIVE TRIGGER
Event: Morepen Laboratories announced Q4 FY26 and FY26 financial results along with operational updates on CDMO commercialization and manufacturing expansion.
Type: Quarterly & Annual Financial Results
Impact: Positive
Immediate Effect: Strong profitability growth, commercial scale-up under the CDMO program and sustained growth in Medical Devices business strengthen Morepen’s medium-term growth visibility and manufacturing-led transformation strategy.
Key Metrics:
- Q4 FY26 Gross Revenue: ₹472 crore | +22% YoY
- Q4 FY26 Net Profit: ₹20 crore | +69% YoY
- Q4 FY26 EBITDA: ₹32 crore vs ₹33 crore in Q4 FY25
- FY26 Standalone Gross Revenue: ₹1,700+ crore | +8% YoY
- Medical Devices Business Growth (Q4 FY26): +31% YoY
- API Business Growth (Q4 FY26): +17% YoY
- Medical Devices Revenue FY26: ₹598 crore | +21% YoY
- Manufacturing Capacity Expansion: ~500 KL to ~800 KL
- Target Long-Term Capacity Roadmap: ~1,000 KL
- Global CDMO Mandate: ₹825 crore / USD 91 million
- Installed Repeat Medical Device User Base: Nearly 17 million users
Highlight:
- Label: Q4 Profit Growth
- Value: Net profit increased 69% YoY to ₹20 crore in Q4 FY26.
What Happened ?
Morepen Laboratories reported strong operational momentum during Q4 FY26 driven by:
- Expansion in the Medical Devices business
- Growth in the API segment
- Commercial execution under its CDMO manufacturing partnership
- Regulated market manufacturing scale-up
The company highlighted:
- Commencement of commercial production under a multi-year CDMO manufacturing program
- Validation batches completed with phased supplies expected shortly
- Capacity expansion underway from ~500 KL to ~800 KL
Management also emphasized:
- Strategic transition from a traditional API-focused business toward a manufacturing-led platform
- Increasing recurring revenues and long-duration customer programs
- Continued investments in devices, healthcare integration and regulated-market capabilities
The Board proposed:
- 10% dividend for FY26
Key Details
CDMO Commercialization, Manufacturing Scale-Up & Devices Expansion:
- Morepen commenced commercial execution under:
- Multi-year CDMO manufacturing partnership program
- Mandate valued at approximately ₹825 crore / USD 91 million
- The company:
- Completed validation batches
- Aligned initial supply schedules
- Expects phased commercial supplies shortly
- Manufacturing expansion underway:
- Capacity scaling from ~500 KL to ~800 KL
- Long-term roadmap toward ~1,000 KL
- API business recorded:
- 17% growth during Q4 FY26
- Medical Devices business:
- Grew 31% YoY during Q4 FY26
- FY26 revenue reached ₹598 crore
- Installed base approached 17 million repeat users
- Medical Devices platform focus areas include:
- Chronic care
- Consumer diagnostics
- Continuous Glucose Monitoring (CGM)
- Connected healthcare integration
- Morepen highlighted:
- Fourth consecutive USFDA inspection completed with NIL 483 observations
- Strong regulated-market compliance track record
- The company indicated strategic investments across:
- Manufacturing scale-up
- Devices expansion
- Customer acquisition
- Healthcare platforms
Note:
- Despite strong revenue and profit growth, EBITDA remained broadly stable in Q4 FY26 due to continued investments in manufacturing expansion, healthcare platforms and regulated-market initiatives.
Risk Analysis
Summary:
- Morepen’s transition toward manufacturing-led CDMO execution and healthcare platform expansion involves execution, scale-up and margin sustainability risks.
Key Risks:
- Commercial execution under large CDMO contracts requires:
- Consistent quality compliance
- Timely supply ramp-up
- Customer retention
- Capacity expansion projects may temporarily pressure:
- Margins
- Working capital
- Near-term profitability
- Pharmaceutical and regulated-market businesses remain exposed to:
- USFDA compliance risks
- Regulatory inspections
- Product approval delays
- Medical Devices business expansion may face:
- Competitive pricing pressure
- Technology adoption risks
- Distribution scaling challenges
- EBITDA moderation during investment phase indicates:
- Near-term operating leverage could remain volatile
Worst Case Scenario:
- Delays in CDMO commercialization, regulatory setbacks or weaker operating leverage from expansion investments could impact profitability and execution visibility over the medium term.
Risk Level: Medium
Company Commentary
- Chairman & Managing Director Sushil Suri stated Morepen is entering the next growth phase focused on:
- Long-duration manufacturing partnerships
- Scale expansion
- Improved operating leverage
- Management stated:
- The company is transitioning from a traditional API model toward a manufacturing-led platform.
- CFO Sanjay Suri highlighted:
- Capacity expansion from ~500 KL toward ~800 KL with roadmap toward ~1,000 KL.
- Management indicated:
- Improved product mix and long-duration supply programs should support stronger margins and earnings visibility.
- The company confirmed:
- Completion of a pivotal bioequivalence study for Resmetirom 100 mg targeting regulated markets outside the US.
- Management stated:
- Medical Devices business continues scaling strongly as a separate high-growth healthcare platform.
Official Exchange Filing: Morepen Laboratories Limited